
The study evaluated the factors associated with adherence to ototoxicity monitoring among head and neck cancer patients treated with cisplatin and radiation therapy. The results showed that 74.8% of patients had at least one post-treatment audiogram, but follow-up rates dramatically decreased after six months. Patients without insurance and those with stage IV cancers were associated with complete loss of audiologic follow-up. Additionally, only 24.8% of patients recommended for a hearing aid received one. The study concluded that further research is needed to understand barriers to long-term audiologic follow-up and hearing aid utilization to decrease untreated hearing loss in cancer survivorship.
Like
Save
Share